Journal article
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
- Abstract:
-
OBJECTIVE: To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the a-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). METHODS: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS > 10 had been analyzed for efficacy. Of these, the 124 patients with severe LUT...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
- Volume:
- 14
- Issue:
- 3
- Pages:
- 326-331
- Publication date:
- 2004-06-01
- ISSN:
-
1166-7087
- Source identifiers:
-
120716
Item Description
- Language:
- French
- Keywords:
- Pubs id:
-
pubs:120716
- UUID:
-
uuid:7b59aa46-123b-48ee-ae33-413408c20c22
- Local pid:
- pubs:120716
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2004
If you are the owner of this record, you can report an update to it here: Report update to this record